Hypothermia Activates Temperature-Sensitive p53 Mutants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors with mutant p53 mutations lack effective therapies, as mutant p53 is resistant to MDM2-mediated ubiquitination and accumulates to high levels, disrupting DNA binding and target gene activation, and wild-type p53 has poor structural stability, making it unable to bind DNA at body temperature.
Innovation Solution
Inducing moderate hypothermia in tumors to activate temperature-sensitive p53 mutations, which enhances the efficacy of chemotherapeutic drugs by maintaining tumor temperatures at 32-34°C for 24-48 hours, using anti-psychotic drugs or core and peripheral cooling methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic drugs are administered to treat tumors with mutant p53, then tumor cell death is induced, but the efficacy is limited because mutant p53 accumulates to high levels and resists MDM2-mediated ubiquitination
Solution Approach 1:
The patent changes the temperature parameter from physiological (37°C) to hypothermic (32-34°C) to activate temperature-sensitive mutant p53 proteins. This parameter change restores p53 function in a subset of mutants, enhancing chemotherapy efficacy by re-establishing the p53-mediated apoptotic pathway that is normally blocked by mutant p53 accumulation.
2Reliability
If wild-type p53 is used to treat tumors, then DNA binding and target gene activation are restored, but structural stability is poor at body temperature
Solution Approach 1:
The patent applies temperature parameter change to stabilize p53 structure. By lowering the temperature to 32-34°C, the structural stability of p53 is improved, allowing it to maintain its tetrameric conformation and DNA-binding capability. This temperature optimization resolves the instability problem of wild-type and mutant p53 at physiological temperature.
3Reliability
If mutant p53 is present in tumors, then resistance to MDM2-mediated ubiquitination occurs, but this leads to high accumulation that disrupts DNA binding
Solution Approach 1:
The patent uses temperature parameter change (hypothermia at 32-34°C) to alter the conformational equilibrium of mutant p53. This parameter change enables temperature-sensitive mutants to adopt the active conformation that can bind DNA and activate target genes, thereby converting the harmful accumulation of mutant p53 into a functional state that restores apoptotic signaling.
4Reliability
If body temperature is maintained at 37°C, then normal physiological functions are preserved, but temperature-sensitive mutant p53 remains inactive
Solution Approach 1:
The patent applies local quality change by inducing hypothermia specifically in the tumor tissue rather than the entire body. This localized temperature reduction (to 32-34°C) activates temperature-sensitive mutant p53 in the tumor while maintaining normal body temperature (37°C) in healthy tissues, thereby achieving selective tumor treatment without systemic side effects.
Solution Approach 2:
The patent changes the temperature parameter locally in the tumor microenvironment to activate mutant p53. By maintaining a temperature gradient between tumor (32-34°C) and normal tissues (37°C), the patent achieves selective activation of p53 function in tumor cells while preserving normal physiological functions in healthy organs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Activates temperature-sensitive p53 mutants, synergizing with chemotherapy to induce tumor regression and durable remission in tumors expressing endogenous ts mutant p53, while avoiding damage to normal tissues.
Implementation Method 1
induce moderate hypothermia in the tumor for a duration sufficient to activate the mutant p53
Implementation Method 2
hypothermia is induced by administering to the subject an effective amount of an anti-psychotic drug
Implementation Method 3
hypothermia is induced with core and/or peripheral cooling of the subject
Data Source
AI summary
Disclosed herein is a method for treating a tumor having a temperature sensitive p53 (ts p53) mutation in a subject in need thereof. The method involves first administering to the subject a therapeutically effective amount of a chemotherapeutic drug, then inducing moderate hypothermia in the tumor for a duration sufficient to activate the mutant p53 to enhance the efficacy of the drug.